In this manuscript, we postulate that XIST represents an important pharmacological target that should be considered in drug development for cardiovascular disease since it is a major epigenetic regulator of gene expression in females, a broad antagonist of miRNAs, and a potential trigger of inflammatory and autoimmune diseases in females. Here, XIST is linked to cardiovascular disorder.